Related Experiment Video

Updated: Jun 18, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Prevalence of prothrombotic polymorphisms in a selected cohort of cryptogenic and noncryptogenic ischemic stroke

Rocco Salvatore Calabrò1, Paolino La Spina, Salvatore Serra

  • 1IRCCS Centro Neurolesi Bonino-Pulejo, Cda Casazza, Messina, Italy. salbro77@tiscali.it

Neurology India
|November 26, 2009
PubMed

Insights

Genetic variations common in prothrombotic states were not significantly more prevalent in young cryptogenic ischemic stroke patients. This suggests other factors contribute to stroke causes in this demographic.

Area of Science:

  • Neurology
  • Genetics
  • Cardiovascular Medicine

Background:

  • Ischemic stroke is a complex condition, with up to 30% of cases, particularly in younger individuals, being cryptogenic (of unknown cause).
  • Prothrombotic states, characterized by genetic predispositions to blood clot formation, are potential underlying factors in cryptogenic ischemic stroke.
  • Identifying genetic risk factors is crucial for understanding stroke etiology and developing targeted prevention strategies, especially in younger populations.

Purpose of the Study:

  • To investigate the prevalence of common genetic polymorphisms associated with prothrombotic states in patients under 55 years of age who experienced ischemic stroke.
  • To determine if specific genetic variations are more common in patients with cryptogenic ischemic stroke compared to those with stroke of a determined cause.

Main Methods:

  • A cohort of 101 ischemic stroke patients under 55 years old was studied.
  • Extensive diagnostic evaluations were performed to identify stroke causes.
  • Genetic analysis focused on common variations in genes for factor V, prothrombin, 5,10-methylenetetrahydrofolate reductase, plasminogen activator inhibitor-1, and human platelet alloantigens-1.

Main Results:

  • Genetic polymorphisms were present in 44% of all patients and 48% of cryptogenic ischemic stroke patients.
  • No significant difference was found in the prevalence of the investigated genetic polymorphisms between patients with cryptogenic ischemic stroke and those with stroke of determined cause.
  • The study included 28 patients with cryptogenic ischemic stroke out of 101 total ischemic stroke patients.

Conclusions:

  • Common genetic polymorphisms related to prothrombotic states do not appear to be a significant distinguishing factor for cryptogenic ischemic stroke in individuals under 55.
  • The findings suggest that other, potentially non-genetic or less common genetic factors, may play a more substantial role in the etiology of cryptogenic ischemic stroke in younger populations.
  • Further research is needed to explore alternative risk factors and genetic markers contributing to stroke in young adults.

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Ischemic Stroke l: Introduction01:15

Ischemic Stroke l: Introduction

Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...